Grail (NASDAQ:GRAL) Now Covered by Analysts at Wolfe Research

Wolfe Research began coverage on shares of Grail (NASDAQ:GRAL) in a research report released on Friday, MarketBeat.com reports. The brokerage issued a peer perform rating on the stock.

Separately, Guggenheim initiated coverage on Grail in a research note on Thursday, October 17th. They issued a “neutral” rating on the stock.

Grail Stock Down 5.4 %

GRAL stock opened at $14.00 on Friday. Grail has a 1 year low of $12.33 and a 1 year high of $23.36. The company has a 50-day moving average of $13.82.

Insider Buying and Selling

In other Grail news, major shareholder Chun R. Ding acquired 35,000 shares of Grail stock in a transaction dated Thursday, October 3rd. The stock was acquired at an average cost of $12.71 per share, for a total transaction of $444,850.00. Following the completion of the transaction, the insider now owns 3,558,655 shares in the company, valued at approximately $45,230,505.05. This represents a 0.99 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Robert P. Ragusa sold 123,454 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total value of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares of the company’s stock, valued at $8,589,507.22. This trade represents a 16.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have acquired a total of 58,829 shares of company stock worth $757,298 over the last quarter.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.